Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death

Multiple myeloma (MM) is a plasma cell neoplasm that results in over 11,000 deaths in the United States annually. The backbone therapy for the treatment of MM patients almost always includes combinations with corticosteroids such as dexamethasone (DEX). We found that DEX in combination with selinexo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Argueta, Christian, Kashyap, Trinayan, Klebanov, Boris, Unger, Thaddeus J., Guo, Cathy, Harrington, Susie, Baloglu, Erkan, Lee, Margaret, Senapedis, William, Shacham, Sharon, Landesman, Yosef
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2018
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5986633/
https://ncbi.nlm.nih.gov/pubmed/29876006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25368
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller